Sökning: onr:"swepub:oai:lup.lub.lu.se:110bc747-4c51-4caf-a0f3-8f508253940c" > Cancer Cells Can Ex...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06072naa a2200541 4500 | |
001 | oai:lup.lub.lu.se:110bc747-4c51-4caf-a0f3-8f508253940c | |
003 | SwePub | |
008 | 210923s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/110bc747-4c51-4caf-a0f3-8f508253940c2 URI |
024 | 7 | a https://doi.org/10.3389/fonc.2021.6861422 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Adrian, Gabrielu Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Strålterapi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Radiation therapy,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)med-gra |
245 | 1 0 | a Cancer Cells Can Exhibit a Sparing FLASH Effect at Low Doses Under Normoxic In Vitro-Conditions |
264 | c 2021-07-29 | |
264 | 1 | b Frontiers Media SA,c 2021 |
520 | a Background: Irradiation with ultra-high dose rate (FLASH) has been shown to spare normal tissue without hampering tumor control in several in vivo studies. Few cell lines have been investigated in vitro, and previous results are inconsistent. Assuming that oxygen depletion accounts for the FLASH sparing effect, no sparing should appear for cells irradiated with low doses in normoxia. Methods: Seven cancer cell lines (MDA-MB-231, MCF7, WiDr, LU-HNSCC4, HeLa [early passage and subclone]) and normal lung fibroblasts (MRC-5) were irradiated with doses ranging from 0 to 12 Gy using FLASH (≥800 Gy/s) or conventional dose rates (CONV, 14 Gy/min), with a 10 MeV electron beam from a clinical linear accelerator. Surviving fraction (SF) was determined with clonogenic assays. Three cell lines were further studied for radiation-induced DNA-damage foci using a 53BP1-marker and for cell cycle synchronization after irradiation. Results: A tendency of increased survival following FLASH compared with CONV was suggested for all cell lines, with significant differences for 4/7 cell lines. The magnitude of the FLASH-sparing expressed as a dose-modifying factor at SF=0.1 was around 1.1 for 6/7 cell lines and around 1.3 for the HeLasubclone. Similar cell cycle distributions and 53BP1-foci numbers were found comparing FLASH to CONV. Conclusion: We have found a FLASH effect appearing at low doses under normoxic conditions for several cell lines in vitro. The magnitude of the FLASH effect differed between the cell lines, suggesting inherited biological susceptibilities for FLASH irradiation. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
650 | 7 | a NATURVETENSKAPx Fysikx Annan fysik0 (SwePub)103992 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Physical Sciencesx Other Physics Topics0 (SwePub)103992 hsv//eng |
653 | a cancer cell lines | |
653 | a clonogenic assay | |
653 | a FLASH | |
653 | a normoxia | |
653 | a radiobiology | |
653 | a radioresistance | |
653 | a radiotherapy | |
653 | a ultra-high dose rate irradiation | |
700 | 1 | a Konradsson, Eliseu Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Radiotherapy Physics,Forskargrupper vid Lunds universitet,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)el0832ko |
700 | 1 | a Beyer, Sarahu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljön,Forskargrupper vid Lunds universitet,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)sa8838be |
700 | 1 | a Wittrup, Andersu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,WCMM- Wallenberg center för molekylär medicinsk forskning,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,WCMM-Wallenberg Centre for Molecular Medicine,Skåne University Hospital4 aut0 (Swepub:lu)medk-awi |
700 | 1 | a Butterworth, Karl T.u Queen's University Belfast4 aut |
700 | 1 | a McMahon, Stephen J.u Queen's University Belfast4 aut |
700 | 1 | a Ghita, Mihaelau Queen's University Belfast4 aut |
700 | 1 | a Petersson, Kristofferu Skåne University Hospital,University of Oxford4 aut0 (Swepub:lu)kr7445pe |
700 | 1 | a Ceberg, Cristeru Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Radiotherapy Physics,Forskargrupper vid Lunds universitet,Rausinglaboratoriet i Lund - Tumörsektionen,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Rausing laboratory of Lund - Tumor section4 aut0 (Swepub:lu)rafy-cce |
710 | 2 | a LUCC: Lunds universitets cancercentrumb Övriga starka forskningsmiljöer4 org |
773 | 0 | t Frontiers in Oncologyd : Frontiers Media SAg 11q 11x 2234-943X |
856 | 4 | u http://dx.doi.org/10.3389/fonc.2021.686142x freey FULLTEXT |
856 | 4 | u https://www.frontiersin.org/articles/10.3389/fonc.2021.686142/pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/110bc747-4c51-4caf-a0f3-8f508253940c |
856 | 4 8 | u https://doi.org/10.3389/fonc.2021.686142 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy